Document Detail

Beta-blockers and coronary flow reserve: the importance of a vasodilatory action.
MedLine Citation:
PMID:  18370439     Owner:  NLM     Status:  MEDLINE    
Coronary flow reserve (CFR) is the maximal increase in coronary blood flow (CBF) above its resting level for a given perfusion pressure when coronary vasculature is maximally dilated. Normally, hyperaemic CBF reaches values at least 2- to 3-fold greater than resting CBF. Reduction of CFR is mainly due to epicardial coronary artery stenosis or to coronary microvascular dysfunction. CFR can be determined by several techniques that measure CBF itself (e.g. positron emission tomography) or CBF velocities (Doppler methods) from which coronary flow velocity reserve is calculated. Hyperaemic coronary vasodilation can be obtained by pharmacological agents (e.g. adenosine and dipyridamole), but also by the cold pressure test. Long-term antihypertensive treatment induces significant improvement of CFR, which is parallel to the regression of left ventricular (LV) hypertrophy. First- and second-generation beta-adrenergic receptor antagonists (beta-blockers) have shown contradictory influences on CFR. This can be explained by the interaction of the effects on CBF at rest, generally reduced by these drugs, and after hyperaemia, when minimal coronary resistance appears to be either increased or reduced. Third-generation beta-blockers (e.g. carvedilol and nebivolol), which have vasodilating capacity, improve hyperaemic CBF. This occurs as a result of a reduction in minimal resistance, which can be attributed to alpha-adrenergic blockade and/or to a nitric oxide-mediated effect. This improvement is clearly beneficial in patients with coronary artery disease and indicates an improved coronary microvascular function. Changes of CFR due to vasodilating beta-blockers improve microvascular angina pectoris or silent ischaemia in patients without epicardial artery stenosis, and are also helpful in predicting the response or the further improvement of LV function to treatment.
Maurizio Galderisi; Arcangelo D'Errico
Related Documents :
17981829 - 64-multislice detector computed tomography coronary angiography as potential alternativ...
12623599 - A case of spontaneous coronary artery disease regression.
2601469 - Incremental network analogue model of the coronary artery.
9768739 - In vivo effects of contrast media on coronary thrombolysis.
21466129 - Surgical resection for ruptured aneurysm of middle colic artery caused by segmental art...
17538759 - Sudden death due to single coronary artery.
21357319 - Does preoperative clopidogrel increase bleeding after coronary bypass surgery?
15658099 - Enlarging vertebrobasilar nonsaccular intracranial aneurysms: frequency, predictors, an...
18365209 - Infectious intracranial aneurysms in the pediatric population: endovascular treatment w...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs     Volume:  68     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  2008  
Date Detail:
Created Date:  2008-03-28     Completed Date:  2008-07-01     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  579-90     Citation Subset:  IM    
Cardioangiology Unit with CCU, Department of Clinical and Experimental Medicine, Federico II University Hospital, Naples, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / pharmacology*
Coronary Circulation / drug effects*
Endothelium, Vascular / drug effects,  physiology
Microcirculation / drug effects
Vasodilator Agents / pharmacology*
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Vasodilator Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Efficacy and safety of once-daily regimens in the treatment of HIV infection.
Next Document:  Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNF...